BioCentury | Aug 2, 2010
Company News

Adagio Pharmaceuticals, Cynapsus deal

...Adagio granted Cynapsus (formerly Cannasat Therapeutics Inc. ) an exclusive option for exclusive, worldwide rights to develop and...
BioCentury | Mar 15, 2010
Company News

Cannasat, IntelGenx deal

...will be responsible for development, costs and commercialization. IntelGenx will forgive about C$231,000 (US$224,396) in Cannasat...
...fee-for-service agreement with Cannasat. Relivar has completed a Phase I trial to treat neuropathic pain. Cannasat Therapeutics Inc....
BioCentury | Feb 15, 2010
Company News

Adagio Pharmaceuticals, Cannasat deal

...The companies signed a letter of intent granting Cannasat an exclusive option to obtain exclusive, worldwide...
...to obtain exclusive, worldwide rights to develop and commercialize Adagio's APL-130277 to treat Parkinson's disease. Cannasat...
...and is in preclinical testing. If Cannasat exercises its option, Adagio would be eligible for Cannasat...
BioCentury | Nov 23, 2009
Company News

Cannasat management update

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario Business: Drug delivery, Neurology Hired: Anthony Giovinazzo as president and CEO, formerly president of the Neuroscience Partners Fund; he replaces David Hill, who remains vice chairman WIR Staff Neurology...
BioCentury | Sep 7, 2009
Financial News

Cannasat completes private placement of units

...1.8 million Price: C$0.10 (unit) Shares after offering: 87.8 million Placement agent: Sandfire Securities Note: Cannasat...
BioCentury | Aug 17, 2009
Financial News

Cannasat completes private placement of units

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario Business: Drug delivery, Neurology Date completed: 8/6/09 Type: Private placement of units Raised: C$750,950 (US$693,728) Units: 7.5 million Price: C$0.10 (unit) Shares after offering: 86 million Placement agent: Sandfire...
BioCentury | Feb 9, 2009
Clinical News

CAT 310: Phase Ib started

...volunteers to evaluate oral CAT 310 vs. Marinol dronabinol from Solvay S.A. (Euronext:SOLB, Brussels, Belgium). Cannasat...
...using IntelGenx's oral transmucosal delivery technology under a 2006 deal (see BioCentury, March 26, 2007). Cannasat Therapeutics Inc....
BioCentury | Jun 30, 2008
Company News

Cannasat, Prairie Plant Systems Inc. deal

...Cannasat divested its 12% equity stake in Prairie for $1.1 million, the amount Cannasat paid for...
...cannabinoid compounds to treat neurological disorders; the deal had been slated to expire in 2016. Cannasat...
...cannabidiol-derived compound that is in preclinical development to treat mood disorders, including anxiety and depression. Cannasat Therapeutics Inc....
BioCentury | Jan 28, 2008
Company News

Cannasat board of directors update

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario Business: Neurology Appointed: Julia Levy, co-founder of QLT Inc. Resigned: Lorne Gertner WIR Staff Neurology...
BioCentury | Mar 26, 2007
Company News

Cannasat, IntelGenx deal

...end. CTH has commercialization rights to both compounds. IGXT is eligible for milestones and royalties. Cannasat Therapeutics Inc....
Items per page:
1 - 10 of 10
BioCentury | Aug 2, 2010
Company News

Adagio Pharmaceuticals, Cynapsus deal

...Adagio granted Cynapsus (formerly Cannasat Therapeutics Inc. ) an exclusive option for exclusive, worldwide rights to develop and...
BioCentury | Mar 15, 2010
Company News

Cannasat, IntelGenx deal

...will be responsible for development, costs and commercialization. IntelGenx will forgive about C$231,000 (US$224,396) in Cannasat...
...fee-for-service agreement with Cannasat. Relivar has completed a Phase I trial to treat neuropathic pain. Cannasat Therapeutics Inc....
BioCentury | Feb 15, 2010
Company News

Adagio Pharmaceuticals, Cannasat deal

...The companies signed a letter of intent granting Cannasat an exclusive option to obtain exclusive, worldwide...
...to obtain exclusive, worldwide rights to develop and commercialize Adagio's APL-130277 to treat Parkinson's disease. Cannasat...
...and is in preclinical testing. If Cannasat exercises its option, Adagio would be eligible for Cannasat...
BioCentury | Nov 23, 2009
Company News

Cannasat management update

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario Business: Drug delivery, Neurology Hired: Anthony Giovinazzo as president and CEO, formerly president of the Neuroscience Partners Fund; he replaces David Hill, who remains vice chairman WIR Staff Neurology...
BioCentury | Sep 7, 2009
Financial News

Cannasat completes private placement of units

...1.8 million Price: C$0.10 (unit) Shares after offering: 87.8 million Placement agent: Sandfire Securities Note: Cannasat...
BioCentury | Aug 17, 2009
Financial News

Cannasat completes private placement of units

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario Business: Drug delivery, Neurology Date completed: 8/6/09 Type: Private placement of units Raised: C$750,950 (US$693,728) Units: 7.5 million Price: C$0.10 (unit) Shares after offering: 86 million Placement agent: Sandfire...
BioCentury | Feb 9, 2009
Clinical News

CAT 310: Phase Ib started

...volunteers to evaluate oral CAT 310 vs. Marinol dronabinol from Solvay S.A. (Euronext:SOLB, Brussels, Belgium). Cannasat...
...using IntelGenx's oral transmucosal delivery technology under a 2006 deal (see BioCentury, March 26, 2007). Cannasat Therapeutics Inc....
BioCentury | Jun 30, 2008
Company News

Cannasat, Prairie Plant Systems Inc. deal

...Cannasat divested its 12% equity stake in Prairie for $1.1 million, the amount Cannasat paid for...
...cannabinoid compounds to treat neurological disorders; the deal had been slated to expire in 2016. Cannasat...
...cannabidiol-derived compound that is in preclinical development to treat mood disorders, including anxiety and depression. Cannasat Therapeutics Inc....
BioCentury | Jan 28, 2008
Company News

Cannasat board of directors update

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario Business: Neurology Appointed: Julia Levy, co-founder of QLT Inc. Resigned: Lorne Gertner WIR Staff Neurology...
BioCentury | Mar 26, 2007
Company News

Cannasat, IntelGenx deal

...end. CTH has commercialization rights to both compounds. IGXT is eligible for milestones and royalties. Cannasat Therapeutics Inc....
Items per page:
1 - 10 of 10